Hims & Hers Health shares technical analysis: Range-bound trading with support at $28.78

Traders Union
All News
Stocks
Hims & hers edges lower to $29.21

Highlights

Hims & Hers Health introduced new injectable and oral testosterone replacement offerings, expanding its presence in the men's health therapeutic area.
The company and certain executives are defendants in a securities class action lawsuit related to alleged violations of consumer health information, billing, and subscription practices.
Shares of Hims & Hers Health trade in a bullish trend with a projected range of $27.6 to $30.82 and a 76% up-move probability.

Product expansion boosts growth prospects amid legal overhang

Hims & Hers Health completed its largest expansion of the men's health program since September 2025 by launching new injectable and oral testosterone replacement therapies, which diversifies its offerings and could help expand long-term revenue streams, according to Morningstar. This product extension positions the company within a growing therapeutic area and may support incremental patient uptake. At the same time, Hims & Hers Health and certain executives face a securities class action lawsuit tied to the FTC's July 29, 2026 federal complaint, alleging violations concerning the handling of consumer health information, premature billing, and subscription cancellation practices, as reported by Prnewswire and Globenewswire. These developments highlight both growth opportunities and emerging regulatory risks for the company in the current market environment.

Bullish positioning sustained as mixed signals temper conviction

On the technical front, price has closed above the MA-20 at $29.14, MA-50 at $28.85, and MA-200 at $27.2 on the hourly chart. Immediate support is highlighted at the Ichimoku Kijun level of $28.78. Momentum indicators present a mixed picture: MACD gives a Strong Buy signal, while ADX is neutral, suggesting limited trend strength. RSI is at 51.58, indicating mild upward bias, with Stochastic RSI in oversold territory and CCI neutral. Bull/Bear Power shows buyers dominating intraday action, whereas the Awesome Oscillator is neutral. The indicators, while skewed toward bullish momentum, are accompanied by diverging oscillator signals that warrant caution.

Consolidation likely as breakout risk shapes short-term outlook

Short-term price action for HIMS is expected to remain within a volatility band of $27.6 to $30.82. With a 76% probability assigned to an upward breakout, consolidation between immediate support and recent highs is the baseline scenario. A move above the upper boundary could prompt a bullish development, while a break below $27.6 would increase downside risks and alter current price dynamics.

Viktoras Karapetjanc, expert at Traders Union, sees Hims & Hers Health showing solid relative strength after its new testosterone therapies launch. He believes the company’s product expansion supports longer-term revenue growth, though the regulatory and legal risks deserve attention. Technical momentum and sentiment remain in buyers’ favor, with a bullish lean if price holds above key support. "I remain constructive as long as HIMS stays above $28.78 — growth drivers still outweigh the current regulatory headwinds."

Previously it was reported that Hims & Hers Health's expansion into the German weight management market and its partnerships positioned the company for potential upside momentum. The latest program diversification and ongoing legal challenges introduce both growth catalysts and heightened regulatory risks, making the $27.6 support area a key level to monitor for shifts in near-term price dynamics.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.